Core Center

核心中心

• 批准号: 8137401
• 负责人: Antony Rosen
• 金额: $ 65.6万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-01 至 2016-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8137401
• 关键词: Core; Center

Patient-oriented biomedical investigation related to diagnosis, disease mechanisms, monitoring disease activity and new therapeutic approaches in rheumatic disease is the hallmark of the Johns Hopkins Division of Rheumatology. This research is structured around well-established disease-specific Centers of Excellence in scleroderma (Dr. Fred Wigley), lupus (Dr. Michelle Petri), arthritis (Dr. Joan Bathon), and vasculitis (Dr. John Stone). These clinical cohorts are coupled closely with a robust basic science program directed by Drs. Antony Rosen and Livia Casciola-Rosen. In recent years, this program has received outstanding institutional support, enabling significant growth, investment in shared equipment and infrastructure, and the initiation of multiple synergistic projects both within and outside the Division. Our Rheumatic Disease Research Core Center (RDRCC) proposal capitalizes upon the strong biomedical research base within the Division of Rheumatology, as well as additional outstanding talent from the broader scientific community at Johns Hopkins. The Hopkins RDRCC proposal comprises an Administrative Core (Core A) led by Drs. Antony Rosen and John Stone, and includes 2 Scientific Cores: 1) a Bioassay Core (Core B), led by Drs. James Mahoney, Mark Soloski, and Livia Casciola-Rosen; and 2) a Genotyping/Genomics Core (Core C), led by Dr. Kathleen Barnes, designed to foster new research within and beyond the Division's Disease Centers. Core A will promote interdisciplinary research through the cores, provide assistance with financial management, provide information technology solutions to maximize efficiency of translational research, and coordinate program enrichment activities. The Administrative core will also manage the Pilot and Feasibility program. Pilot studies chosen for the first year are tightly linked to the disease Centers and Cores. Pilot #1 will optimize assays to quantify clearance of apoptotic cells directly ex vivo in pediatric SLE patients. Pilot #2 will explore the association of genetic polymorphisms in granzyme B with specific phenotypes in scleroderma. Core B will provide assistance with patient sample acquisition, processing, storage, and distribution, as well as the provision of multiple immunological assays, including FACS, ELISA, immunohistology, and multiplex cytokine assays. Core C will perform, analyze, and interpret gene expression studies in a variety of human disease and control tissues and some mouse models. Core C will also oversee the design, performance and analysis of genetic association studies in well-defined human rheumatic phenotypes.

与诊断，疾病机制，监测疾病活动和风湿病疾病的新治疗方法有关的以患者为导向的生物医学研究是约翰·霍普金斯风湿病学的标志。这项研究围绕着良好的疾病特异性卓越中心（Fred Wigley博士），狼疮（Michelle Petri博士），关节炎（Joan Bathon博士）和血管炎（John Stone博士）。这些临床人群与DRS指导的强大基础科学计划紧密相结合。 Antony Rosen和Livia Casciola-Rosen。近年来，该计划获得了出色的机构支持，可以实现大幅增长，对共享设备和基础设施的投资以及该部门内外的多个协同项目的启动。我们的风湿病研究核心中心（RDRCC）提案资本利用了风湿病分工的强大生物医学研究基础，以及约翰·霍普金斯（Johns Hopkins）更广泛的科学界的其他杰出人才。 霍普金斯RDRCC提案包括由DRS领导的行政核心（核心A）。安东尼·罗森（Antony Rosen）和约翰·斯通（John Stone），包括2个科学核心：1）由Drs领导的生物测定核心（核心B）。 James Mahoney，Mark Soloski和Livia Casciola-Rosen； 2）由凯瑟琳·巴恩斯（Kathleen Barnes）博士领导的基因分型/基因组核心（Core C），旨在促进该师疾病中心内外的新研究。核心A将通过核心促进跨学科研究，为财务管理提供帮助，提供信息技术解决方案以最大化转化研究的效率，并协调计划丰富的活动。行政核心还将管理飞行员和可行性计划。第一年选择的试点研究与疾病中心和核心密切相关。试点＃1将优化测定方法，以量化小儿SLE患者直接离体凋亡细胞清除率。飞行员＃2将探索颗粒状B中遗传多态性与硬皮病中特定表型的关联。核心B将在患者样品获取，加工，存储和分布以及提供多种免疫学测定方面提供帮助，包括FACS，ELISA，免疫组织学和多重细胞因子分析。核心C将在各种人类疾病和控制组织以及某些小鼠模型中执行，分析和解释基因表达研究。 Core C还将监督定义明确的人类风湿性表型中遗传关联研究的设计，性能和分析。